Scynexis Inc

NASDAQ:SCYX   1:11:17 PM EDT
2.75
-0.07 (-2.48%)
Products

Scynexis Announces U.S. FDA Acceptance And Priority Review Of The Supplemental New Drug Application For Brexafemme® (Ibrexafungerp Tablets) For Prevention Of Recurrent Vaginal Yeast Infections

Published: 08/01/2022 14:38 GMT
Scynexis Inc (SCYX) - Scynexis Announces U.S. Food and Drug Administration Acceptance and Priority Review of the Supplemental New Drug Application for Brexafemme® (ibrexafungerp Tablets) for Prevention of Recurrent Vaginal Yeast Infections.
Scynexis Inc - Submission Has Been Granted Priority Review and Given a Target Regulatory Decision Date of November 30, 2022.